Pharmaceuticals

Rated

Abbott	U.S.	B
Abbvie	U.S.	C-
Actelion	Switzerland	B
Active Biotech	Sweden	B-
Amgen	U.S.	C-
Amicus Therapeutics	U.S.	C-
Aspen Pharmacare	South Africa	A-
Astellas Pharma	Japan	B+
Astrazeneca	UK	A-
Baxter	U.S.	C+
BD (Becton Dickinson)	U.S.	C+
Biogen	U.S.	B-
Bristol-Myers Squibb	U.S.	B
Celgene	U.S.	B-
Chugai Pharmaceutical	Japan	B+
Cipla	India	C+
Coloplast	Denmark	C+
Daiichi Sankyo	Japan	B+
Dr. Reddy's Laboratories	India	B
Eisai	Japan	B+
Fresenius Medical Care	Germany	B+
Gilead Sciences	U.S.	B-
GSK (GlaxoSmithKline)	UK	B+
Ipsen	France	B+
Johnson & Johnson	U.S.	C+
Lilly (Eli Lilly)	U.S.	C+
Lundbeck	Denmark	B
Lupin	India	B
Medtronic	U.S.	C
Merck	Germany	B+
Merck & Co	U.S.	C
Mitsubishi Tanabe Pharma	Japan	B+
Neuland Laboratories	India	C+
Novartis	Switzerland	B+
Novo Nordisk	Denmark	A-
Octapharma	Switzerland	B-
Perrigo	Ireland	C+
Pfizer	U.S.	B
Roche	Switzerland	B+
Sanofi	France	B
Shire	Ireland	B
Sobi	Sweden	B+
Sun Pharma	India	B
Takeda Pharmaceutical	Japan	B
Teva Pharmaceuticals	Israel	C-
UCB	Belgium	B+
Valeant Pharmaceuticals	Canada	C+

Ranked

Screenshot of Novo Nordisk's annual report 2016

Novo Nordisk	Denmark	A-
Aspen Pharmacare	South Africa	A-
Astrazeneca	UK	A-
Mitsubishi Tanabe Pharma	Japan	B+
GSK (GlaxoSmithKline)	UK	B+
Novartis	Switzerland	B+
Roche	Switzerland	B+
Astellas Pharma	Japan	B+
Merck	Germany	B+
Daiichi Sankyo	Japan	B+
Sobi	Sweden	B+
Chugai Pharmaceutical	Japan	B+
Fresenius Medical Care	Germany	B+
Eisai	Japan	B+
UCB	Belgium	B+
Ipsen	France	B+
Abbott	U.S.	B
Lundbeck	Denmark	B
Shire	Ireland	B
Takeda Pharmaceutical	Japan	B
Dr. Reddy's Laboratories	India	B
Pfizer	U.S.	B
Sun Pharma	India	B
Actelion	Switzerland	B
Bristol-Myers Squibb	U.S.	B
Lupin	India	B
Sanofi	France	B
Biogen	U.S.	B-
Active Biotech	Sweden	B-
Gilead Sciences	U.S.	B-
Celgene	U.S.	B-
Octapharma	Switzerland	B-
Perrigo	Ireland	C+
Johnson & Johnson	U.S.	C+
Neuland Laboratories	India	C+
Lilly (Eli Lilly)	U.S.	C+
BD (Becton Dickinson)	U.S.	C+
Baxter	U.S.	C+
Cipla	India	C+
Valeant Pharmaceuticals	Canada	C+
Coloplast	Denmark	C+
Medtronic	U.S.	C
Merck & Co	U.S.	C
Abbvie	U.S.	C-
Amgen	U.S.	C-
Teva Pharmaceuticals	Israel	C-
Amicus Therapeutics	U.S.	C-

Compared (A)

Chart comparing pharmaceuticals companies

Compared (B)

Chart comparing pharmaceuticals companies

Benchmarked (A)

Chart benchmarking pharmaceuticals companies

Benchmarked (B)

Chart benchmarking pharmaceuticals companies

Noticed

Aspen Pharmacare

Very good introduction, based on 5 capitals; eight reasons to invest; clear strategic objectives; peer company comparatives; smart use of KPIs. All of those make up an example of integrated reporting.

Astellas Pharma

Highlights centered around the real business: R&D (topics shown later), number of new entities in the pipeline (further developed), collaborative research projects, medical representatives... Results and Plans for CSR finely summed up.

Astrazeneca

Between actual and constant rate of exchange, core and reported operating profit (net is left out) Financial highlights are more light than enlightening. More substantial content follows: e.g. Business model and life-cycle of a medicine, Marketplace, KPIs, pipeline progressions in each therapy area...

Daiichi Sankyo

Integration of business and CSR activities, challenges and strategic targets put very clearly in the Value Report. Pipeline and Major Products made intelligible, too.

Dr. Reddy's Laboratories

Gives a satisfactory account on some aspects but is too short on substance in a number of areas.

Eisai

Though not always an easy read (some pages are cluttered with texts and data), it proves a fine achiever of integrated reporting, including on Financial Capital and related Strategies.

Fresenius Medical Care

The main report is informative -e.g. about financing, risks, a detailed outlook- but a bit dull. A lively magazine goes along and provides more Living Knowledge -literally.

Lupin

The inside layout isn’t really up to the front cover magazine style but the topic-based thread does it finely, at least in the first (book) quarter. The rest is a tedious read.

Merck

The Magazine section is enticing, also in its online format. The 250-page-plus Report is more... serious, e.g. in its thorough Review of Forecast against Actual Business Developments (with a quarterly breakdown).

Mitsubishi Tanabe Pharma

Crystal-clear presentation of Business Portfolio and Processes. Pipeline highlighted right after financial and other indicators, before a substantial Message from the President and a robust chapter about Drug Discovery.

Novartis

In an effort to build Novartis into a company that can thrive no matter what the future holds (sic), we made significant changes in 2016 to create a more sustainable company. (CEO’s letter) For the present (or recent past), turn the page: most key figures went down. Why did the loss of one single US patent protection weigh so much? Nice photography.

Octapharma

A breathtaking thread made of pictures runs through the whole report of the family-owned Swiss human protein product company. Financial matters lag behind.

Pfizer

The online Annual Review gives a good... view. As to the Financial Report PDF, probably made in dullsville, many readers will quickly take their eyes off the ball.